-$0.08 Earnings Per Share Expected for Sesen Bio Inc (NASDAQ:SESN) This Quarter

Wall Street brokerages expect Sesen Bio Inc (NASDAQ:SESN) to post ($0.08) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Sesen Bio’s earnings, with estimates ranging from ($0.08) to ($0.07). Sesen Bio reported earnings per share of ($0.18) in the same quarter last year, which suggests a positive year-over-year growth rate of 55.6%. The company is scheduled to issue its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Sesen Bio will report full year earnings of ($0.85) per share for the current financial year, with EPS estimates ranging from ($0.86) to ($0.83). For the next year, analysts anticipate that the firm will post earnings of ($0.41) per share, with EPS estimates ranging from ($0.42) to ($0.39). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Sesen Bio.

Sesen Bio (NASDAQ:SESN) last released its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04).

A number of equities analysts recently commented on SESN shares. HC Wainwright upgraded Sesen Bio from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $1.00 to $3.00 in a report on Tuesday, June 11th. Laidlaw cut Sesen Bio from a “buy” rating to a “hold” rating in a report on Friday, August 9th. ValuEngine upgraded Sesen Bio from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Sesen Bio from a “sell” rating to a “hold” rating and set a $1.25 price target for the company in a report on Wednesday. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Sesen Bio has an average rating of “Hold” and a consensus price target of $2.42.

A number of institutional investors have recently bought and sold shares of SESN. CVI Holdings LLC bought a new position in Sesen Bio during the second quarter worth about $12,169,000. Millennium Management LLC boosted its holdings in shares of Sesen Bio by 32.5% during the fourth quarter. Millennium Management LLC now owns 1,099,897 shares of the company’s stock worth $1,562,000 after acquiring an additional 269,863 shares during the period. Monashee Investment Management LLC bought a new stake in shares of Sesen Bio during the second quarter worth approximately $300,000. Wells Fargo & Company MN boosted its holdings in shares of Sesen Bio by 5,692.4% during the second quarter. Wells Fargo & Company MN now owns 99,976 shares of the company’s stock worth $150,000 after acquiring an additional 98,250 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Sesen Bio during the first quarter worth approximately $88,000. Institutional investors and hedge funds own 24.27% of the company’s stock.

Sesen Bio stock traded up $0.01 during midday trading on Monday, reaching $1.12. 752,500 shares of the company’s stock were exchanged, compared to its average volume of 1,302,557. Sesen Bio has a 52 week low of $0.66 and a 52 week high of $2.60. The stock’s 50-day simple moving average is $1.24 and its 200 day simple moving average is $1.25.

About Sesen Bio

Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.

Further Reading: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on Sesen Bio (SESN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sesen Bio (NASDAQ:SESN)

Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.